SG11201404321YA - Humanized antibodies that recognize alpha-synuclein - Google Patents
Humanized antibodies that recognize alpha-synucleinInfo
- Publication number
- SG11201404321YA SG11201404321YA SG11201404321YA SG11201404321YA SG11201404321YA SG 11201404321Y A SG11201404321Y A SG 11201404321YA SG 11201404321Y A SG11201404321Y A SG 11201404321YA SG 11201404321Y A SG11201404321Y A SG 11201404321YA SG 11201404321Y A SG11201404321Y A SG 11201404321YA
- Authority
- SG
- Singapore
- Prior art keywords
- synuclein
- humanized antibodies
- recognize alpha
- alpha
- recognize
- Prior art date
Links
- 102000003802 alpha-Synuclein Human genes 0.000 title 1
- 108090000185 alpha-Synuclein Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591835P | 2012-01-27 | 2012-01-27 | |
| US201261711207P | 2012-10-08 | 2012-10-08 | |
| PCT/US2013/023307 WO2013112945A1 (en) | 2012-01-27 | 2013-01-25 | Humanized antibodies that recognize alpha-synuclein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404321YA true SG11201404321YA (en) | 2014-08-28 |
Family
ID=48873980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404321YA SG11201404321YA (en) | 2012-01-27 | 2013-01-25 | Humanized antibodies that recognize alpha-synuclein |
Country Status (22)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141568A1 (es) | 2011-10-28 | 2014-11-21 | Neotope Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleina |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| PT3016681T (pt) * | 2013-07-05 | 2020-03-26 | Genmab As | Anticorpos humanizados ou quiméricos cd3 |
| CA2924268C (en) * | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| CN106568969B (zh) * | 2016-10-19 | 2017-09-26 | 首都医科大学 | 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法 |
| EP3548074A4 (en) * | 2016-12-02 | 2020-07-01 | Prothena Biosciences Limited | INFRARED ASSAY DETECTING SECONDARY ALPHA-SYNUCLEIN STRUCTURE PROFILES |
| CN110494445B (zh) | 2017-01-06 | 2023-10-20 | Abl生物公司 | 抗α-SYN抗体及其用途 |
| KR102573778B1 (ko) * | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
| KR102826089B1 (ko) * | 2017-08-02 | 2025-06-30 | 스트레스마크 바이오사이언시즈 인코퍼레이티드 | 활성 알파 시누클레인에 결합하는 항체 |
| WO2019117685A2 (ko) * | 2017-12-14 | 2019-06-20 | 에이비엘바이오 주식회사 | 항-igf1r 항체 및 그 용도 |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| CN112839710B (zh) | 2018-08-09 | 2024-09-17 | 霍夫曼-拉罗奇有限公司 | 帕金森氏病的确定 |
| CN112888708A (zh) * | 2018-10-19 | 2021-06-01 | 扬森疫苗与预防公司 | 抗突触核蛋白抗体 |
| AU2020358854A1 (en) * | 2019-10-03 | 2022-05-26 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| IL296664A (en) | 2020-04-24 | 2022-11-01 | Hoffmann La Roche | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
| IL300059A (en) * | 2020-07-23 | 2023-03-01 | Othair Prothena Ltd | Anti-Abata antibodies |
| TW202309076A (zh) * | 2021-05-12 | 2023-03-01 | 南韓商Ａｂｌ生物公司 | 用於治療α-突觸核蛋白病之抗體 |
| CN113912714B (zh) * | 2021-12-15 | 2022-02-22 | 北京凯祥弘康生物科技有限公司 | 特异性结合α-突触核蛋白的抗体及其应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| CN100489892C (zh) | 1999-02-05 | 2009-05-20 | 三星电子株式会社 | 恢复描述图像的纹理特征的图像纹理描述符的方法及装置 |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US7657380B2 (en) * | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| WO2004039234A2 (en) | 2002-05-13 | 2004-05-13 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| AU2003302689B2 (en) | 2002-11-29 | 2009-02-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel neomycin phosphotransferase genes and method for the selection of high-producing recombinant cells |
| JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US7930064B2 (en) * | 2004-11-19 | 2011-04-19 | Parata Systems, Llc | Automated drug discrimination during dispensing |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| US7892544B2 (en) | 2006-07-14 | 2011-02-22 | Ac Immune Sa | Humanized anti-beta-amyloid antibody |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| HUE034512T2 (en) * | 2007-01-05 | 2018-02-28 | Univ Zuerich | A method for providing disease-specific binding molecules and targets |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| EP2064242A1 (en) | 2007-02-23 | 2009-06-03 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| WO2008107388A1 (en) | 2007-03-02 | 2008-09-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improvement of protein production |
| WO2008116149A2 (en) | 2007-03-22 | 2008-09-25 | Genentech, Inc. | Apoptotic anti- ige antibodies binding the membrane-bound ige |
| KR20090113340A (ko) | 2007-03-22 | 2009-10-29 | 임클론 엘엘씨 | 안정한 항체 제제 |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| AU2008340429C1 (en) | 2007-12-21 | 2016-09-08 | F. Hoffmann-La Roche Ag | Antibody formulation |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| LT2282758T (lt) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
| WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| DE102008048129A1 (de) | 2008-09-20 | 2010-04-22 | Lfk-Lenkflugkörpersysteme Gmbh | Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper |
| BRPI0923157B1 (pt) | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
| CN109172813B (zh) | 2009-07-28 | 2022-09-02 | 武田药品工业株式会社 | 用于治疗戈谢病的组合物和方法 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20130116413A1 (en) | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2795279C (en) * | 2010-04-08 | 2020-05-05 | Jn Biosciences Llc | Antibodies to cd122 |
| KR101839163B1 (ko) * | 2010-06-08 | 2018-03-15 | 제넨테크, 인크. | 시스테인 조작된 항체 및 접합체 |
| TR201807750T4 (tr) * | 2010-06-11 | 2018-06-21 | Kyowa Hakko Kirin Co Ltd | Anti-TIM-3 antikoru. |
| KR101695056B1 (ko) * | 2010-07-15 | 2017-01-10 | 애드헤론 쎄라퓨틱스, 인코포레이티드 | 카드헤린-11의 ec1 도메인을 표적으로 하는 인간화 항체 및 관련 조성물 및 방법 |
| WO2012051147A1 (en) | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
| US20140050733A1 (en) | 2011-02-07 | 2014-02-20 | Dale B. Schenk | Apoe immunotherapy |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| JP6061922B2 (ja) | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
| JP2014522843A (ja) | 2011-06-30 | 2014-09-08 | ジェネンテック， インコーポレイテッド | 抗ｃ−ｍｅｔ抗体製剤 |
| PE20141568A1 (es) | 2011-10-28 | 2014-11-21 | Neotope Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleina |
| CN116077644A (zh) | 2011-10-31 | 2023-05-09 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| MY178542A (en) | 2012-08-29 | 2020-10-15 | Hoffmann La Roche | Blood brain barrier shuttle |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2013
- 2013-01-25 AU AU2013211874A patent/AU2013211874B2/en not_active Ceased
- 2013-01-25 MX MX2014008952A patent/MX360778B/es active IP Right Grant
- 2013-01-25 US US13/750,983 patent/US8790644B2/en not_active Expired - Fee Related
- 2013-01-25 WO PCT/US2013/023307 patent/WO2013112945A1/en not_active Ceased
- 2013-01-25 DK DK13740871.2T patent/DK2807188T3/da active
- 2013-01-25 NZ NZ629296A patent/NZ629296A/en not_active IP Right Cessation
- 2013-01-25 RU RU2014134747A patent/RU2642262C2/ru active
- 2013-01-25 MY MYPI2014002199A patent/MY171140A/en unknown
- 2013-01-25 IN IN7149DEN2014 patent/IN2014DN07149A/en unknown
- 2013-01-25 ES ES13740871T patent/ES2749457T3/es active Active
- 2013-01-25 JP JP2014554890A patent/JP6342333B2/ja not_active Expired - Fee Related
- 2013-01-25 KR KR1020147024060A patent/KR102086061B1/ko not_active Expired - Fee Related
- 2013-01-25 KR KR1020207006200A patent/KR102246217B1/ko not_active Expired - Fee Related
- 2013-01-25 CN CN201380007018.8A patent/CN104619724B/zh not_active Expired - Fee Related
- 2013-01-25 CN CN201810297949.0A patent/CN108517010A/zh active Pending
- 2013-01-25 EP EP13740871.2A patent/EP2807188B1/en active Active
- 2013-01-25 BR BR112014018561A patent/BR112014018561A8/pt active Search and Examination
- 2013-01-25 SG SG11201404321YA patent/SG11201404321YA/en unknown
- 2013-01-25 CA CA2863953A patent/CA2863953A1/en not_active Abandoned
- 2013-01-25 UA UAA201409460A patent/UA115439C2/uk unknown
-
2014
- 2014-07-24 MX MX2018014044A patent/MX2018014044A/es unknown
- 2014-07-24 US US14/340,355 patent/US9217030B2/en not_active Expired - Fee Related
- 2014-07-24 PH PH12014501685A patent/PH12014501685A1/en unknown
- 2014-07-24 US US14/340,342 patent/US9234031B2/en not_active Expired - Fee Related
- 2014-07-25 CL CL2014001984A patent/CL2014001984A1/es unknown
- 2014-07-27 IL IL233829A patent/IL233829B/en active IP Right Grant
- 2014-08-25 ZA ZA2014/06227A patent/ZA201406227B/en unknown
-
2015
- 2015-11-10 US US14/937,792 patent/US9670273B2/en not_active Expired - Fee Related
-
2017
- 2017-05-04 US US15/587,255 patent/US10118960B2/en not_active Expired - Fee Related
-
2018
- 2018-05-16 JP JP2018094968A patent/JP6807893B2/ja not_active Expired - Fee Related
- 2018-09-27 US US16/144,923 patent/US10597441B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/795,479 patent/US10875909B2/en not_active Expired - Fee Related
-
2021
- 2021-03-22 IL IL281731A patent/IL281731A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201406227B (en) | Humanized antibodies that recognize alpha-synuclein | |
| ZA201403864B (en) | Humanized antibodies that recognize alpha-synuclein | |
| IL258940B (en) | Anti–il–23p19 antibodies | |
| ZA201502213B (en) | Antibodies recognizing alpha-synuclein | |
| IL234102A0 (en) | Bispecific igg4 antibodies are aligned symmetrically to the sequence | |
| IL234942A0 (en) | A tau antibody of human origin | |
| IL235042B (en) | Anti–fcrn antibodies | |
| IL234848A0 (en) | Protease controlled antibodies | |
| ZA201407272B (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| SG10201709290XA (en) | Anti-H7cr Antibodies | |
| IL235188A0 (en) | Antibodies against c-pdgf |